Table 3. . Dosing examples of therapeutic options for managing ipilimumab immune-related adverse events.

Immune-related adverse event	Management strategies
	Grade
	Mild	Severe
Dermatologic	Diphehydramine 25–50 mg po q6h prn	Prednisone/equivalent 1–2 mg/kg po die
	Hydrorxyzine 25–50 mg po q6h prn	×4 weeks then taper over at least 30 days
	Urea 10–22% loc appl prn
	Hydrating cream loc appl prn
	Hydrocortisone 1% or betamethasone 0.1% loc appl prn
Gastrointestinal	Loperamide 2 mg po prn max 16 mg/day	Methylprednisolone 125 mg iv. × 1 then
	Diphenoxylate/atropine 1–2 tabs po q6–8 h prn	Prednisone 1–2 mg/kg or
	Hydration	Dexamethasone 4 mg po q4h then taper over at least 30 days
	Electrolyte substitution	Infliximab 5 mg/kg iv. q2 weeks until relief then steroid taper over 45–60 days
Endocrine	–	Methylprednisolone 1–2 mg/kg iv. ×1 then prednisone 1–2 mg/kg po die then taper over 4 weeks + hydrocortisone po
Hepatic	–	High dose glucocorticoid iv. ×24–48 h then dexamethasone 4 mg po q4h or prednisone 1–2 mg/kg taper over at least 30 days
		Mycophenolate mofetil
		Tacrolimus
		Infliximab

die: Daily; po: Per os; prn: If needed; q6h: Every 6 h.

Data taken from [10,12].